Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 165

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

Open access
Tai, Yu-Tzu, Chang, Betty Y., Kong, Sun-Young, Fulciniti, Mariateresa, Yang, Guang, Calle, Yolanda, Hu, Yiguo, Lin, Jianhong, Zhao, Jian-Jun, Cagnetta, Antonia, Cea, Michele, Sellitto, Michael A., Zhong, Mike Y., Wang, Qiuju, Acharya, Chirag, Carrasco, Daniel R., Buggy, Joseph J., Elias, Laurence, Treon, Steven P., Matsui, William, Richardson, Paul, Munshi, Nikhil C., Anderson, Kenneth C.·2012·Blood

Abstract

Bruton tyrosine kinase (Btk) has a well-defined role in B-cell development, whereas its expression in osteoclasts (OCs) further suggests a role in osteoclastogenesis. Here we investigated effects of PCI-32765, an oral and selective Btk inhibitor, on osteoclastogenesis as well as on multiple myeloma (MM) growth within the BM microenvironment. PCI-32765 blocked RANKL/M-CSF–induced phosphorylation of Btk and downstream PLC-γ2 in OCs, resulting in diminished TRAP5b (ED50 = 17nM) and bone resorption activity. PCI-32765 also inhibited secretion of multiple cytokines and chemokines from OC and BM stromal cell cultures from both normal donors (ED50 = 0.5nM) and MM patients. It decreased SDF-1–induced migration of MM cells, and down-regulated MIP1-α/CCL3 in MM cells. It also blocked MM cell growth and survival triggered by IL-6 or coculture with BM stromal cells or OCs in vitro. Importantly, PCI-32765 treatment significantly inhibits in vivo MM cell growth (P < .03) and MM cell–induced osteolysis of implanted human bone chips in SCID mice. Moreover, PCI-32765 prevents in vitro colony formation by stem-like cells from MM patients. Together, these results delineate functional sequelae of Btk activation mediating osteolysis and growth of MM cells, supporting evaluation of PCI-32765 as a novel therapeutic in MM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-12-396853

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 5 references

Cited by

See all 165

Metadata

Authors
Tai, Y.-T., Chang, B. Y., Kong, S.-Y., Fulciniti, M., Yang, G., Calle, Y., Hu, Y., Lin, J., Zhao, J.-J., Cagnetta, A., Cea, M., Sellitto, M. A., Zhong, M. Y., Wang, Q., Acharya, C., Carrasco, D. R., Buggy, J. J., Elias, L., Treon, S. P., Matsui, W., Richardson, P., Munshi, N. C., & Anderson, K. C.
Venue
Blood
Published
2012-08-30
Volume
120
Issue
9
Pages
1877-1887
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2125678285
Cited by
165
References
5
FWCI
16.33
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. https://app.cochat.ai/papers/10.1182/blood-2011-12-396853
The paper
Tai, Y.-T., Chang, B. Y., Kong, S.-Y., Fulciniti, M., Yang, G., Calle, Y., Hu, Y., Lin, J., Zhao, J.-J., Cagnetta, A., Cea, M., Sellitto, M. A., Zhong, M. Y., Wang, Q., Acharya, C., Carrasco, D. R., Buggy, J. J., Elias, L., Treon, S. P., . . . Anderson, K. C. (2012). Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. https://doi.org/10.1182/blood-2011-12-396853

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.